(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pulmonary Arterial Hypertension pipeline constitutes 55+ key companies continuously working towards developing 55+ Pulmonary Arterial Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Pulmonary Arterial Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Pulmonary Arterial Hypertension Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Arterial Hypertension Market.
Some of the key takeaways from the Pulmonary Arterial Hypertension Pipeline Report:
- Companies across the globe are diligently working toward developing novel Pulmonary Arterial Hypertension treatment therapies with a considerable amount of success over the years.
- Pulmonary Arterial Hypertension companies working in the treatment market are Topadur Pharma, Centessa Pharmaceuticals, Ribomic, Gmax Biopharm, ATXA Therapeutics, Aerami Therapeutics, PhaseBio Pharmaceuticals, Altavant Sciences, Respira Therapeutics, Aerovate Therapeutics, United Therapeutics Corporation, Pharmosa Biopharm, Merck, and others, are developing therapies for the Pulmonary Arterial Hypertension treatment
- Emerging Pulmonary Arterial Hypertension therapies in the different phases of clinical trials are- TOP – V122, MGX292, RBM-011, Getagozumab, NTP42, AER-901, Pemziviptadil (PB1046), Rodatristat Ethyl, RT234, AV-101, Ralinepag, L606, Sotatercept, and others are expected to have a significant impact on the Pulmonary Arterial Hypertension market in the coming years.
- In July 2022, Cereno Scientific announced that the first patient had been enrolled in the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1.
- In June 2022, Gossamer Bio, Inc. announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH).
- In March 2022, Acceleron Pharma initiated a Phase 3, randomized, double-blind,placebo-controlled study to evaluate Sotatercept when added to background pulmonary arterial hypertension(PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients. The trial is currently recruiting participants and is expected to be completed by June 2028 with 662 participants.
- In November 2021, Merck known as MSD outside the United States and Canada, announced the successful completion of the acquisition of Acceleron Pharma Inc.
Pulmonary Arterial Hypertension Overview
Elevated pulmonary vascular resistance is a common trait among a diverse range of illnesses collectively referred to as pulmonary arterial hypertension. Patients frequently arrive with vague complaints of increasing weakness and dyspnea with physical activity.
Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight
Emerging Pulmonary Arterial Hypertension Drugs Under Different Phases of Clinical Development Include:
- TOP – V122: Topadur Pharma
- MGX292: Centessa Pharmaceuticals
- RBM-011: Ribomic
- Getagozumab: Gmax Biopharm
- NTP42: ATXA Therapeutics
- AER-901: Aerami Therapeutics
- Pemziviptadil (PB1046): PhaseBio Pharmaceuticals
- Rodatristat Ethyl: Altavant Sciences
- RT234: Respira Therapeutics
- AV-101: Aerovate Therapeutics
- Ralinepag: United Therapeutics Corporation
- L606: Pharmosa Biopharm
- Sotatercept: Merck
Pulmonary Arterial Hypertension Route of Administration
Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Pulmonary Arterial Hypertension Molecule Type
Pulmonary Arterial Hypertension Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment
- Pulmonary Arterial Hypertension Assessment by Product Type
- Pulmonary Arterial Hypertension By Stage and Product Type
- Pulmonary Arterial Hypertension Assessment by Route of Administration
- Pulmonary Arterial Hypertension By Stage and Route of Administration
- Pulmonary Arterial Hypertension Assessment by Molecule Type
- Pulmonary Arterial Hypertension by Stage and Molecule Type
DelveInsight’s Pulmonary Arterial Hypertension Report covers around 55+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Pulmonary Arterial Hypertension product details are provided in the report. Download the Pulmonary Arterial Hypertension pipeline report to learn more about the emerging Pulmonary Arterial Hypertension therapies
Some of the key companies in the Pulmonary Arterial Hypertension Therapeutics Market include:
Key companies developing therapies for Pulmonary Arterial Hypertension are – Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Actelion Pharmaceuticals, Ltd., Merck & Co. Inc., Novartis International, Pfizer, Inc., United Therapeutics, and others.
Pulmonary Arterial Hypertension Pipeline Analysis:
The Pulmonary Arterial Hypertension pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.
- Pulmonary Arterial Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Pulmonary Arterial Hypertension drugs and therapies
Pulmonary Arterial Hypertension Pipeline Market Drivers
- Rising prevalence of Pulmonary Arterial Hypertension worldwide, increasing investment for healthcare infrastructure, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Pulmonary Arterial Hypertension Market.
Pulmonary Arterial Hypertension Pipeline Market Barriers
- However, high cost associated with the treatment of Pulmonary Arterial Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Pulmonary Arterial Hypertension Market growth.
Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight
- Coverage: Global
- Key Pulmonary Arterial Hypertension Companies: Topadur Pharma, Centessa Pharmaceuticals, Ribomic, Gmax Biopharm, ATXA Therapeutics, Aerami Therapeutics, PhaseBio Pharmaceuticals, Altavant Sciences, Respira Therapeutics, Aerovate Therapeutics, United Therapeutics Corporation, Pharmosa Biopharm, Merck, and others
- Key Pulmonary Arterial Hypertension Therapies: TOP – V122, MGX292, RBM-011, Getagozumab, NTP42, AER-901, Pemziviptadil (PB1046), Rodatristat Ethyl, RT234, AV-101, Ralinepag, L606, Sotatercept, and others
- Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
- Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers
Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials
Table of Contents
1. Pulmonary Arterial Hypertension Report Introduction
2. Pulmonary Arterial Hypertension Executive Summary
3. Pulmonary Arterial Hypertension Overview
4. Pulmonary Arterial Hypertension- Analytical Perspective In-depth Commercial Assessment
5. Pulmonary Arterial Hypertension Pipeline Therapeutics
6. Pulmonary Arterial Hypertension Late Stage Products (Phase II/III)
7. Pulmonary Arterial Hypertension Mid Stage Products (Phase II)
8. Pulmonary Arterial Hypertension Early Stage Products (Phase I)
9. Pulmonary Arterial Hypertension Preclinical Stage Products
10. Pulmonary Arterial Hypertension Therapeutics Assessment
11. Pulmonary Arterial Hypertension Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pulmonary Arterial Hypertension Key Companies
14. Pulmonary Arterial Hypertension Key Products
15. Pulmonary Arterial Hypertension Unmet Needs
16 . Pulmonary Arterial Hypertension Market Drivers and Barriers
17. Pulmonary Arterial Hypertension Future Perspectives and Conclusion
18. Pulmonary Arterial Hypertension Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Pulmonary Arterial Hypertension Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | GSK, J&J, Arena Pharma, Bayer, Bristol-Myers Squibb
